Immuneering Co. (NASDAQ:IMRX – Free Report) – Stock analysts at Chardan Capital upped their FY2024 earnings per share (EPS) estimates for Immuneering in a research report issued on Monday, September 16th. Chardan Capital analyst G. Livshits now forecasts that the company will earn ($1.61) per share for the year, up from their previous forecast of ($1.64). Chardan Capital has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Immuneering’s current full-year earnings is ($1.90) per share. Chardan Capital also issued estimates for Immuneering’s FY2025 earnings at ($0.75) EPS.
Immuneering (NASDAQ:IMRX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05.
Check Out Our Latest Analysis on Immuneering
Immuneering Trading Up 6.1 %
IMRX stock opened at $2.42 on Wednesday. The firm has a 50-day moving average price of $1.28 and a 200-day moving average price of $1.82. Immuneering has a 12 month low of $1.00 and a 12 month high of $9.00. The stock has a market capitalization of $71.76 million, a P/E ratio of -1.29 and a beta of -0.61.
Institutional Trading of Immuneering
A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Immuneering by 12.1% in the 1st quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock valued at $3,479,000 after acquiring an additional 129,851 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Immuneering in the second quarter worth $67,000. Renaissance Technologies LLC acquired a new stake in Immuneering in the second quarter valued at $447,000. XTX Topco Ltd raised its position in Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after purchasing an additional 9,274 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Immuneering during the 2nd quarter worth about $492,000. 67.65% of the stock is owned by institutional investors and hedge funds.
About Immuneering
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Featured Stories
- Five stocks we like better than Immuneering
- ESG Stocks, What Investors Should Know
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- The Most Important Warren Buffett Stock for Investors: His Own
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Canada Bond Market Holiday: How to Invest and Trade
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.